Last reviewed · How we verify
Metastatic basal cell carcinoma
Approved treatments
- Libtayo · Regeneron Pharmaceuticals
Cemiplimab-rwlc binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, enhancing the immune response against tumors.
Clinical guidelines
- FDA label — 2L
ERIVEDGE is indicated for the treatment of adults with metastatic basal cell carcinoma. - FDA label — 2L
ERIVEDGE is indicated for the treatment of adults with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery and who are not candidates for radiation.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Metastatic basal cell carcinoma patent landscape — cliff calendar, originator estates, attackable patents
- Metastatic basal cell carcinoma treatment landscape brief
- Metastatic basal cell carcinoma treatment updates RSS
Frequently asked questions about Metastatic basal cell carcinoma
What drugs treat Metastatic basal cell carcinoma?
Tracked treatments include Libtayo.
What is the treatment for Metastatic basal cell carcinoma?
Standard treatment for Metastatic basal cell carcinoma includes Libtayo. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Metastatic basal cell carcinoma?
FDA label publishes guidelines for Metastatic basal cell carcinoma. 2 guideline references tracked.
Related
- Treatment landscape: Metastatic basal cell carcinoma patent cliff · Metastatic basal cell carcinoma CI report
- Treatment: Libtayo · Regeneron Pharmaceuticals
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing